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Collagen VI is an integral part of the skeletal muscle extracellular matrix, providing mechanical stability and
facilitating matrix-dependent cell signaling. Mutations in collagen VI result in either Ullrich congenital mus-
cular dystrophy (UCMD) or Bethlem myopathy (BM), with UCMD being clinically more severe. Recent studies
demonstrating increased apoptosis and abnormal mitochondrial function in Col6a1 knockout mice and in
human myoblasts have provided the ﬁrst mechanistic insights into the pathophysiology of these diseases.
However, how loss of collagen VI causes mitochondrial dysfunction remains to be understood. Progress
is hindered in part by the lack of an adequate animal model for UCMD, as knockout mice have a mild
motor phenotype. To further the understanding of these disorders, we have generated zebraﬁsh models of
the collagen VI myopathies. Morpholinos designed to exon 9 of col6a1 produced a severe muscle disease
reminiscent of UCMD, while ones to exon 13 produced a milder phenotype similar to BM. UCMD-like zebraﬁsh
have increased cell death and abnormal mitochondria, which can be attenuated by treatment with the proton
pump modiﬁer cyclosporin A (CsA). CsA improved the motor deﬁcits in UCMD-like zebraﬁsh, but failed to
reverse the sarcolemmal membrane damage. In all, we have successfully generated the ﬁrst vertebrate
model matching the clinical severity of UCMD and demonstrated that CsA provides phenotypic improvement,
thus corroborating data from knockout mice supporting the use of mitochondrial permeability transition pore
modiﬁers as therapeutics in patients, and providing proof of principle for the utility of the zebraﬁsh as a
powerful preclinical model.
INTRODUCTION
Abnormalities in the extracellular matrix are common in
human muscular dystrophies (1). Stable attachments between
the matrix and the receptors on the surface of the sarcolemmal
membrane are required for providing mechanical stability to
the contracting muscle ﬁber. These contacts are also important
for mediating signal transduction events that regulate diverse
cellular processes, including muscle cell regeneration, pro-
liferation and survival (2).
Collagen VI is an essential component of the myoﬁber
extracellular matrix. Mutations in collagen VI result in two
allelic conditions, Ullrich congenital muscular dystrophy
(UCMD) and Bethlem myopathy (BM) (3). UCMD is a
severe congenital disorder characterized by neonatal hypoto-
nia, weakness and the combination of joint hyperlaxity and
severe progressive contractures (4,5). UCMD is associated
with signiﬁcant morbidity and mortality (6). Most patients
either never ambulate or lose their ability to do so, and the
majority of affected individuals eventually require the need
for ventilatory support. Life expectancy is reduced, largely
as a result of respiratory failure. BM, on the other hand, is a
milder myopathy characterized by later onset, slower pro-
gression and largely preserved ambulation (7–9). Patients
with BM also exhibit the characteristic combination of
initial joint laxity followed by progressive contractures
(3,10). The true incidences of UCMD and BM are unknown.
Recent studies have shown that UCMD is the second most
common congenital muscular dystrophy, accounting for
between 20 and 30% of all cases (10).
Collagen VI is a complex macromolecule made up of equal
parts of COL6A1, COL6A2 and COL6A3 (11). Collagen VI is
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extracellular matrix (3,12,13). Individual collagen VI subunits
are combined to form triple helical monomers. These mono-
mers are then assembled into antiparallel dimers, and then
into tetramers. The tetrameric collagen VI is secreted into
the extracellular milieu. Once outside the ﬁbroblasts, the tetra-
mers are further aligned into microﬁbrils, which represent the
functional collagen VI macromolecule (11,14,15). Microﬁbrils
have been demonstrated to form attachments with several mol-
ecules, including other components of the extracellular matrix
(biglycan and collagen IV) and adhesion receptors on the
surface of the myoﬁber (integrins) (3,13). One of the main pro-
posed functions for collagen VI is promoting the stability of
the sarcolemmal membrane during muscle contractions
(1,16). It has also been implicated in a variety of other pro-
cesses, including basement membrane assembly, and cell sig-
naling events such as cell survival and regulation of myoﬁber
size (3). However, much still remains to be understood about
the in vivo functions of the collagen VI microﬁbril.
Mutations in any of the three collagen VI subunits,
(COL6A1, COL6A2 and COL6A3), can result in muscle
disease (4,5,17). UCMD can result from either recessive or
dominant mutations (18,19). Recessive mutations are typically
loss of function mutations, with the result being signiﬁcant
reduction in the synthesis of one collagen VI subunit and
secondary overall reduction or absence of secreted collagen
VI macromolecules (3), although recessive missense
mutations have also been described. Heterozygous UCMD
mutations, on the other hand, probably act through a
dominant-negative mechanism (20,21). They are most often
found in exons that code for the N-terminal part of the triple
helical domain. They result in collagen VI subunits that can
be assembled into monomers, dimers and tetramers, but with
impaired ability to be assembled into proper microﬁbrils.
BM was originally characterized as a dominant disorder,
although there is clear evidence for recessive inheritance as
well (22,23). Mutations in Bethlem most often result in col-
lagen VI subunits that assemble into triple helical monomers,
but are not able to be processed further (3). Thus, they reduce
the overall amount of collagen VI that is secreted.
Currently, there are no treatments available for either
UCMD or BM. Recently, a potential therapeutic avenue has
been identiﬁed, largely through the use of a mouse model of
collagen VI myopathies. This mouse strain has a germline
mutation in Col6a1, and 2/2 recessive animals exhibit a
very mild clinical myopathy with histopathologically abnor-
mal muscle (24). Irwin et al.( 25) found abnormalities in the
mitochondrial structure and aspects of its function in these
mice. Speciﬁcally, they observed that the mice had swollen/
dilated mitochondria which had lost their normal proton
charge gradient, and that these abnormalities in mitochondria
led to an increased myoﬁber apoptosis. They further found
that modiﬁcation in the mitochondrial permeability transition
pore (or PTP), either pharmacologically with cyclosporin A
(CsA) or genetically by knockout of cyclophilin D, improved
the mitochondrial changes and reduced myoﬁber cell death
(25–27). They then found similar abnormalities in the mito-
chondrial structure and function in patients with collagen VI
myopathies, as well as increased cell death (28). This has ulti-
mately lead to the proposed use of PTP modiﬁers such as CsA
or a synthetic analog called debio-025 as treatments for col-
lagen VI myopathies (29,30).
It is currently unclear how interruption of collagen VI func-
tionresultsinabnormalitiesinmitochondrialfunction.Onepro-
posed mechanism is that tears or leaks in the sarcolemmal
membrane, a known phenomenon in collagen VI myopathies,
cause a rise in intracellular calcium (29). The increased intra-
cellular calcium causes mitochondrial swelling, which, in
turn, disturbs the PTP and leads to the release of the
pro-apoptoticfactorcytochromeC.Thistheoryhasyettoberig-
orously tested. Furthermore, it is not known to what extent cor-
rectionofthemitochondrialabnormalitieswillaffectthedisease
process in humans. PTP modiﬁers are not expected to improve
the loss of stable extracellular matrix attachments to the
musclemembraneandthesubsequentdisturbanceinmembrane
integrityinUCMDandBM.Onebiglimitationinthepreclinical
evaluation of the PTP modiﬁers is the fact that Col6a12/2
micehavesuchanextremelymildphenotypethattheyareprob-
ably best used as a model of mild BM (24). Therefore, although
CsA does improve the muscle histology in 2/2 mice (25), it is
difﬁculttopredictwhateffectitwillhaveinthesettingofsevere
muscle weakness, as seen in the UCMD.
Given the lack of a more robust model for severe collagen VI
muscular dystrophies, we generated a model of UCMD using
zebraﬁsh. Such a model could then be used as a springboard
for future therapeutic studies for treating the severe form of
thesediseases.Ourmodelusesantisensemorpholinotechnology
in the developing zebraﬁsh embryo. Injection of morpholino to
zebraﬁsh exon 9 of col6a1 resulted in an in-frame deletion in
the N-terminal part of the triple helical domain, paralleling the
dominant mutations in UCMD (31,32). As would be predicted,
this morpholino caused a severe myopathy with early-onset
development motor deﬁcits and severe ultrastructural changes.
Injection of morpholino to exon 13 resulted in an in-frame del-
etionintheC-terminal partofthetriplehelicaldomain,parallel-
ing a typical dominant BM mutation (32,33). This morpholino
resulted in a mild myopathy with late-onset motor deﬁcits and
obvious histopathologic abnormalities. We further analyzed
the exon 9 morpholino to characterize its potential utility as a
UCMD model. We observed mitochondrial swelling and
increased apoptosis, consistent with the changes observed in
patients with UCMD. We tested the effect of CsA in this
model, and found that it decreased apoptosis, improved mito-
chondrial appearance and improved overall motor function.
Importantly, we found that the effect of CsA was ‘upstream’ of
apoptosis, as correcting apoptosis itself did not improve motor
function. On the other hand, the effect was ‘downstream’ of
plasma membrane damage, as treatment with CsA did not
improve membrane integrity. These results demonstrate that
we have successfully developed the ﬁrst vertebrate model with
clinical severity that matches that of UCMD. We provide evi-
dence that PTP modiﬁers such as CsA can induce functional
and structural improvements in this model, and propose that
these drugs should be investigated in patients with UCMD.
RESULTS
Morpholino knockdown of zebraﬁsh col6a1
As previously reported, there are single copies in the
zebraﬁsh genome of COL6A1, COL6A2 and COL6A3 (34).
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human COL6A1, exon 9 is the equivalent of exon 10. Exon
10 encodes a portion of the N-terminal triple helical domain,
and it is a common site for dominant mutations in UCMD.
Deletion of exon 9 from zebraﬁsh col6a1 is predicted to
result in an in-frame truncated transcript that should function
as a dominant negative and generate a UCMD-like phenotype.
Injection of exon 9 morpholino into 1–2-cell stage embryos
resulted in the reduction of the normal col6a1 transcript and
in the appearance of a novel truncated transcript (Supplemen-
tary Material, Fig. S1A, arrow). Direct sequencing of the trun-
cated transcript conﬁrmed an in-frame deletion of exon 9 (data
not shown). Exon 13 is the equivalent of exon 14 in human
COL6A1. Exon 14 is a commonly deleted exon in BM. Del-
etion of zebraﬁsh exon 13 is predicted to cause an in-frame
deletion that should result in a BM-like phenotype. Injection
of exon 13 morpholino resulted in the reduction of normal
transcript and the production of an in-frame, truncated tran-
script (Supplementary Material, Fig. S1B).
Knockdown of zebraﬁsh col6a1 results in developmental
motor abnormalities
We analyzed motor function at 24 and 48 h post fertilization
(hpf) using two validated motor assays (35): spontaneous
coiling (at 24 hpf) and touch-evoked escape response (at
48 hpf). Embryos injected with exon 9 morpholino exhibited
severe abnormalities with both assays (Fig. 1A and B). The
average number of spontaneous coiling events per 15 s was
1.5 (+0.4, six trials, n ¼ 69) as compared to 7.0 (+0.4,
n ¼ 138) for embryos injected with a scrambled control mor-
pholino (P , 0.0001; Fig. 1A). The average touch-evoked
escape response (as graded on a 0–3 scale; see Materials
and Methods section) was 0.3 (+0.1, 3 trials, n ¼ 23) as com-
pared to 2.6 (+0.1, n ¼ 66; P , 0.0001; Fig. 1B). Embryos
injected with exon 13 morpholino, on the other hand, had
normal spontaneous coiling but a mild and statistically signiﬁ-
cant decrease in touch-evoked escape response. The average
number of coiling events was 6.6 (+0.5, three trials, n ¼
82, P . 0.05 when compared with control; Fig. 1A), while
the average touch-evoked escape response was 1.8 (+0.1, 3
trials, n ¼ 52, P , 0.0001 when compared with controls;
Fig. 1B).
Morphologic changes in col6a1 morphants
We then examined morpholino-injected (i.e. morphant)
embryos for morphologic changes using live light microscopy.
In total, 94.5% of exon 9 morphants exhibited severe abnorm-
alities in their overall appearance (n ¼ 74 over ﬁve indepen-
dent injections). At 24 hpf, exon 9 embryos were shorter
overall, had hypoplastic midbodies and had bent, foreshor-
tened tails (Fig. 2B). At 48 hpf, these embryos continued to
have an obviously dysmorphic appearance. They were sub-
stantially shorter than control embryos, had small midbodies
and tails and also were often bent into a C-shape (Fig. 2E).
Given that the midbody and tail are primarily composed of
skeletal muscle compartments, these changes are consistent
with a primary muscle pathology and have previously been
reported in other zebraﬁsh models of muscular dystrophy
and myopathy (35–39). Of note, 84.6% of embryos injected
with half concentration of exon 9 morpholino exhibited the
same phenotypic (both motor and morphologic) changes
(n ¼ 78, data not shown).
Injection with exon 13 morpholino, on the other hand, did
not result in obvious morphologic changes at either 24
(Fig. 2C) or 48 hpf (Fig. 2F; n ¼ 82). This is consistent with
the mild motor phenotype detailed above and with our predic-
tion that exon 13 morphants would resemble a BM-like
phenotype.
Validation of phenotypic speciﬁcity using a col6a3
morpholino
To test the speciﬁcity of the changes observed in the col6a1
morphant embryos for collagen VI disruption, we performed
additional experimentation with a morpholino designed to
Figure 1. Motor abnormalities in col6a1 morphant zebraﬁsh. (A) Spontaneous
coiling as measured at 24 hpf. Exon 9 morphant embryos (ex9 MO) had sig-
niﬁcant reduction in the number of coiling events observed in 15 s when com-
pared with controls (CTL MO). Exon 13 morphants (ex13 MO) had normal
spontaneous coiling. Average values were 7.0 (CTL), 1.5 (ex9) and 6.6
(ex13). (B) Touch-evoked escape response as measured at 48 hpf. Exon 9 mor-
phants were severely impaired in this behavior, whereas exon 13 morphants
had a mild but statistically signiﬁcant decrease in activity. Average values
were 2.6 (CTL), 0.3 (ex9) and 1.8 (ex13).
Human Molecular Genetics, 2010, Vol. 19, No. 12 2435exon 9 of the col6a3 gene. Deletion of exon 9 in zebraﬁsh
col6a3 resulted in an in-frame, truncated transcript that is pre-
dicted to function as a dominant-negative mutation (data not
shown). This exon is equivalent to human exon 16 of
COL6A3, and heterozygous deletion of this exon has been
reported in several UCMD patients. Morpholino knockdown
of exon 9 in col6a3 caused a severe phenotype with both sig-
niﬁcant motor deﬁciencies and widespread morphologic
changes (data not shown). The average number of spontaneous
coils per 15 s for col6a3 morphants was 2.6 (+0.6, n ¼ 40) as
compared to 7.9 (+1.2, n ¼ 21) for controls (P , 0.0001).
The phenotype with this morpholino was essentially identical
to that observed with the exon 9 col6a1 morpholino, and
demonstrated that the severe morpholino-dependent pheno-
types are speciﬁc for alterations in collagen VI and not due
to non-speciﬁc, off-target effects.
Col6a1 morpholino injection alters collagen VI antibody
staining
We examined collagen VI antibody staining as an additional
test of the speciﬁcity of our col6a1 morpholino. Whole-mount
antibody labeling of 48 hpf control embryos with an antibody
to collagen VI revealed a ﬁne reticulated pattern in the somatic
compartment (arrow, Fig. 3A). Antibody labeling of exon 9
morphant embryos, on the other hand, gave an abnormal
pattern of staining. Label was diminished overall and instead
found in small clumps scattered throughout the myoﬁber com-
partment (Fig. 3B). Such a pattern is consistent with staining
previously reported for some UCMD patients with dominant
mutations (3).
Col6a1 morphant skeletal muscle exhibits histopathologic
alterations
Skeletal muscle from col6a1 exon 9 and exon 13 morphant
embryos was examined by light microscopy at 48 hpf (n ¼ 4
embryos per condition). Multiple abnormalities were noted
in exon 9 embryos, both at the sarcolemmal membrane and
within the myoﬁbers (Fig. 4B). The primary adhesion
interface between the extracellular matrix and the plasma
membrane in zebraﬁsh muscle is at the myotendinous junc-
tion. This junction was nearly unrecognizable in the exon 9
morphants, lacking the dense band of staining seen in controls
Figure 2. Morphologic abnormalities in col6a1 morphant zebraﬁsh. Micro-
scopic analysis of live embryos at 24 hpf (A–C) and 48 hpf (D–F). Exon 9
morphants were small, with hypoplasic and bent midbodies and tails (B and
E). They also had mild pericardial edema, a ﬁnding often seen with reduced
movement. Exon 13 morphants were grossly normal in appearance at both
24 hpf (C) and 48 hpf (F).
Figure 3. Collagen VI antibody labeling in col6a1 morphant zebraﬁsh. Whole-
mount immunoﬂuorescent analysis was performed on control (CTL MO) and
exon 9 (Ex9 MO) morpholino-injected embryos at 48 hpf. CTL MO embryos
(A) demonstrated a ﬁne, reticulated pattern of staining with their myotomes
(arrow). Ex9 MO embryos (B), conversely, had diminished staining that was
present in unusual patches (arrows). Dashed lines indicate the boundaries of
the muscle compartment. n ¼ 6 per condition. Scale bar ¼ 1 mm.
Figure 4. Microscopic abnormalities in col6a1 morphant zebraﬁsh. Semi-thin
sections stained with toluidine blue of 48 hpf zebraﬁsh embryos. Muscle from
control morphants is presented in (A). In contrast to controls, muscle from
exon 9 morphants exhibited multiple changes (B). Within the sarcoplasm,
theseincludedvacuolatedareas(darkarrows),nucleiwithcondensedchromatin
(white areas), and areas of amorphous material (∗∗). In addition, myotendinous
junctions were difﬁcult to distinguish and had decreased intensity of staining
(arrowheads).Musclefromexon13morphantsalsorevealedhistologicabnorm-
alities (C,D). Mild changes were observed in some embryos, and included thin-
ning of the myotendinous junction (arrowheads, C). More severe changes were
seeninothers(D),andincludedareasofswelling(blackarrows)andnucleiwith
condensed chromatin (white arrows). Scale bar ¼ 20 mm.
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that lacked staining were noted (dark arrows, Fig. 4B and D);
these probably represent dilated mitochondria and sarcoplas-
mic reticulum (see below). There were also places of
obvious myoﬁber damage, where normal structure was
replaced with opaque, amorphous materials (Fig. 4B, aster-
isks). In addition, several myonuclei had condensed chroma-
tin, consistent with cells undergoing apoptosis (white
arrows). Overall, the ﬁndings were consistent with a dys-
trophic muscle process. Of note, despite these widespread
changes, myoﬁbrils (Z bands and actin/myosin cross bridges)
were present and appeared normal.
Skeletalmusclefromexon13morphantsexhibitedarangeof
changes. Some myoﬁbers had only subtle histologic abnormal-
ities (Fig. 4C). Other ﬁbers exhibited many of the changes seen
in the exon 9 morphants. In particular, areas of hypodensity
wereobserved(arrows),aswerenucleiwithcondensedchroma-
tin(whitearrows;Fig.4D).Aswiththeexon9morphants,myo-
ﬁbrils were normal in appearance. However, even in muscle
ﬁbers with more obvious structural changes, the myotendinous
junctions were less affected, with preservation of some areas of
dense staining matrix material (arrowheads).
Col6a1 morphant skeletal muscle has severe
ultrastructural abnormalities
Col6a1 morphant embryos have ultrastructural abnormalities
that mirror the changes observed by light microscopy (n ¼ 4
embryos per condition). Analysis of exon 9 morphants at
48 hpf revealed abnormalities in multiple areas of the myoﬁ-
ber. The most striking intracellular changes were in the mito-
chondria and the endoplasmic reticulum (ER). When
compared with controls, perinuclear mitochondria were
large, swollen, and had many fewer distinguishable cristae
(Fig. 5A and B). Single membrane structures corresponding
to ER were also swollen and enlarged (Fig. 5A and C).
These changes are consistent with those observed in Col6a1
knockout mice and in patients with UCMD (see Supplemen-
tary Material, Fig. S2 for comparison) (25,28).
In addition, the myotendinous junctions in exon 9 mor-
phants appeared to be obviously abnormal. The extracellular
matrix had a paucity of electron dense material, and the sarco-
lemmal membrane was thin with numerous small discontinu-
ities (arrow, Fig. 6B). There was also a signiﬁcant increase
in the number of peri-membranous mitochondria (M in
Fig. 6C). We quantitated this observation, and found that, on
average, there were 16.0 (+0.6, n ¼ 8) mitochondria per
high-powered ﬁeld in exon 9 morphants. Conversely, only
5.8 (+0.6, n ¼ 6) per ﬁeld were observed in control
embryos (P , 0.0001).
Exon 13 morphants also exhibited ultrastructural abnormal-
ities (Fig. 6D). Similar, though less dramatic, changes in mito-
chondria and ER were observed. The myotendinous junction
also had decreased electron density (arrow). Severe membrane
tears were observed in some places (Fig. 6D, asterisks). These
areas of membrane rupture were more extensive than those
observed in exon 9 morphants, which may be due to the fact
that exon 13 embryos were more active than exon 9 morphants
(see Fig. 2), and thus their muscle was exposed to greater
mechanical stress.
Figure 5. Ultrastructural changesin organelles in col6a1 exon 9 morphant zeb-
raﬁsh.Electronmicroscopicanalysison48 hpfmorphantembryos.Ascompared
to controls (A), exon 9 morphant embryos have abnormalities in intracellular
organelles (B,C). Speciﬁcally, mitochondria are swollen with abnormal cristae
(M, B), and endoplasmic reticulum are dilated (ER, C). These changes are con-
sistent with those reported in patients with Ullrich CMD. Scale bar ¼ 500 nm.
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caused by col6a1 morpholinos are consistent with a mild,
Bethlem-like phenotype (exon 13 morpholino) and with a
severe, UCMD-like phenotype (exon 9 morpholino).
Because we were most interested in generating and studying
a model of UCMD, for the remaining analysis we focused
on the exon 9 morphant embryos.
Assessment of apoptosis in col6a1 exon 9 morphant
embryos
Histologic examination of col6a1 exon 9 morphant skeletal
muscle suggested that apoptosis was increased in these
embryos. We further examined and quantitated this obser-
vation using TUNEL staining. Exon 9 morphants had signiﬁ-
cantly increased numbers of apoptotic myonuclei when
compared with controls. Representative TUNEL stained
exon 9 and control morphant embryos are depicted in
Figure 7A (see also Supplementary Material, Fig. S3). The
results of the quantitative analysis are presented in
Figure 7B. On average, there were 11.5 (+2.4, n ¼ 13) apop-
totic myonuclei in exon 9 morphants versus only 3.2 (+0.3,
n ¼ 29) for control morphants (P , 0.0001).
It has previously been demonstrated in col6a1 knockout
mice and in UCMD patient myocytes that treatment with
CsA reduces the amount of apoptosis (25,28). We therefore
tested the effect of CsA on cell death in our zebraﬁsh exon
9 morphants (Fig. 7). As expected, CsA reduced the average
number of apoptotic cells from 11.5 to 7.5 (+1.0, n ¼ 16,
P ¼ 0.05). This result corroborates the effect of CsA on apop-
tosis seen in mammalian models and thus supports the validity
of the exon 9 morphant zebraﬁsh as an accurate model of
severe collagen VI myopathy.
Another well-characterized method for reducing apoptosis
in zebraﬁsh is knockdown of the p53 tumor suppressor gene
using a p53-speciﬁc morpholino (40). Co-injection of the
p53 morpholino with the exon 9 morpholino also reduced
apoptosis from 11.5 to 6.2 (+1.2, n ¼ 25, P ¼ 0.01;
Fig. 7B). There was no statistical difference in the reduction
in apoptosis between p53 knockdown and CsA treatment, as
well as no difference in apoptosis between either condition
alone and p53 morpholino + CsA treatment (Fig. 7B).
CsA treatment improves motor function in col6a1 exon 9
morphants
To determine the effect of CsA treatment on the severely
impaired motor function in exon 9 morphant embryos,
embryos were injected with morpholino at the 1–2-cell
stage, dechorionated at 20 hpf, treated with CsA for 3 h
(21–24 hpf), and then analyzed for spontaneous coiling at
24 hpf (Fig. 8). We observed an obvious improvement in spon-
taneous coiling after only 3 h of treatment. CsA-treated
embryos had, on average, 4.1 coiling events in 15 s (+0.7,
n ¼ 30), as compared to 1.2 events in vehicle (DMSO)-treated
exon 9 morphants (+1.2, n ¼ 27, P ¼ 0.003). Recovery was
not complete, however, as exon 9 morphants treated with
CsA still had reduced movements when compared with
DMSO-treated embryos (4.1 versus 6.8, n ¼ 35 for controls,
P ¼ 0.009). Remarkably, CsA not only improved the overall
Figure 6. Sarcoplasmic ultrastructural changes in col6a1 morphant zebraﬁsh.
(A) Normal myotendinous junction in control morphant embryos (arrow, CTL
MO). (B) Myotendinous junctions in exon 9 morphants show multiple
abnormalities (arrow). The sarcoplasmic membranes are thinned with small
rips/breaks, and the surrounding extracellular matrix is broad and less dense.
(C) An excessive number of mitochondria were present in the sub-
membranous area of exon 9 morphants. (D) Ultrastructural changes in exon
13 morphants. These include swollen/dilated endoplasmic reticulum (ER),
abnormal myotendonous junctions (arrow) and large areas of subsarcolemmal
disorganization (∗∗∗). Scale bar ¼ 500 nm.
2438 Human Molecular Genetics, 2010, Vol. 19, No. 12number of coiling events, but also signiﬁcantly reduced the
percentage of completely paralyzed embryos (DMSO versus
CsA, 59+7% versus 33+6%, P ¼ 0.006).
To test whether the effect of CsA was solely a result of its
anti-apoptotic properties, we compared motor function of
CsA-treated embryos with those co-injected with p53 and
exon 9 morpholinos (Fig. 8). Despite the signiﬁcant reduction
in apoptosis caused by p53 knockdown (see Fig. 4B), double
morphant embryos did not show improvement in spontaneous
coiling (DMSO versus p53, 1.2 versus 1.2, n ¼ 29 for exon
9 + p53). Also, there was no signiﬁcant difference in motor
function of exon 9 morphants between CsA treatment and
CsA treatment + p53 morpholino injection (data not shown).
CsA treatment improves the ultrastructural appearance of
exon 9 morphants
CsA treatment would be predicted to improve the appearance
of mitochondria in exon 9 morphant skeletal muscle (25). We
performed electron microscopic analysis of CsA and vehicle-
treated exon 9 morphant embryos to test this (Fig. 9). CsA-
treated morphant embryos had clear improvements in their
mitochondria (Fig. 9B). The mitochondria were less swollen
and had an increase in the density and complexity of their
cristae. DMSO-treated morphants, on the other hand, had
swollen, dysmorphic mitochondria that were indistinguishable
in appearance from those seen with exon 9 morpholino alone
(Fig. 9A, and see Fig. 3). Similar improvement in mitochon-
dria appearance has been described with CsA treatment of
Col6a1 knockout mice (25).
CsA treatment does not improve sarcolemmal membrane
appearance and overall myoﬁber integrity
We ﬁnally assessed the effect of CsA treatment on the struc-
tural appearance of the sarcolemmal membrane and on
overall myoﬁber integrity. As shown in Figures 2 and 3, the
sarcolemmal membrane and the surrounding extracellular
Figure 7. Apoptosis in col6a1 morphant zebraﬁsh. (A) Representative images of whole-mount TUNEL staining on morphant embryos. Control embryos (CTL
MO) have very few TUNEL-positive cells. Exon 9 morphants (COL6) have an increased number of TUNEL-positive cells. Boxed cells and those indicated
by the arrow are positive myonuclei. The number of positive cells is reduced in exon 9 morphants by co-injection with p53 morpholino (COL6 + p53 MOs)
or by treatment with cyclosporin A (COL6 MO+ CsA). (B) Quantitation of TUNEL-positive myonuclei. An average number of positive cells are as
follows: CTL ¼ 3.2, COL6 ¼ 11.5, COL6 + p53 ¼ 6.2, COL6 + CsA ¼ 7.5, and COL6 + CsA + p53 ¼ 6.2.
Human Molecular Genetics, 2010, Vol. 19, No. 12 2439matrix are severely disturbed in exon 9 morphants. We exam-
ined the myotendinous junctions in CsA and DMSO-treated
exon 9 morphant embryos, using electron microscopy. We
found no obvious differences between them, detecting
similar abnormalities to those seen with exon 9 morpholino
injection alone (data not shown).
We also evaluated the effect of CsA on myoﬁber integrity
and organization using a quantitative assessment of skeletal
muscle birefringence. Birefringence, the reﬂected appearance
of muscle under polarized light, is a normal property of
intact muscle that indicates proper myoﬁber organization
and is a surrogate measure of myoﬁber integrity (37).
Reduced birefringence has been reported in several zebraﬁsh
models of muscular dystrophy (36,37). Embryos injected
with exon 9 morpholino have signiﬁcantly reduced birefrin-
gence (as measured at 48 hpf), consistent with the dystrophic
changes observed by electron microscopy (Fig. 6). Birefrin-
gence is easily quantiﬁed by measuring the mean intensity
of a ﬁxed portion of the embryo (Fig. 10). Exon 9 morphants
had an average birefringence intensity of 30.5 (+3.1, n ¼ 21).
Conversely, control embryos had an average intensity of 128.7
(+16.4, n ¼ 21, P , 0.0001). To determine the effect of CsA
treatment on membrane integrity, we measured the mean
intensity of birefringence in treated embryos. The average
value was 42.1 (+8.7, n ¼ 21), a value that was not statisti-
cally different from untreated exon 9 morphants (P ¼ 0.2).
As with untreated embryos, this value was also signiﬁcantly
lower than that measured for control embryos (P , 0.0001).
DISCUSSION
Both BM and UCMD are allelic conditions caused by abnorm-
alities in collagen VI and characterized by the combination of
weakness, hypermobility and contractures (3). UCMD is the
second most common congenital muscular dystrophy and is
associated with progressive symptoms and with signiﬁcant
morbidity and mortality (6,10). No current treatments exist
for either condition, and an animal model that mirrors the
severity of UCMD is lacking. We present here the ﬁrst ver-
tebrate model with a severe motor phenotype that equates
with UCMD. We used antisense morpholino technology to
generate zebraﬁsh embryos with dominant-negative transcripts
of col6a1 that result in severe morphologic, structural and
functional changes.
The validity of our zebraﬁsh model is supported by several
observations. The ﬁrst is that many of the ultrastructural
changes that have been reported in patients with collagen VI
myopathies were observed in the skeletal muscle of morphant
embryos, including swelling and dilation of the mitochondria
and ER (29). These pathologic ﬁndings, also present in the
muscle of Col6a1 knockout mice, are relatively unique to
BM and UCMD patients, and are not a common feature of
all congenital muscular dystrophies (25). They have been
reported, however, in congenital muscular dystrophy due to
mutation in the LAMA2 gene (27). Another consistent
ﬁnding was the increase in cell death observed in the morphant
zebraﬁsh. Increased apoptosis is a well-characterized phenom-
enon in collagen VI myopathy patient biopsy samples (28). A
third observation is the gradation of severity observed with our
two morpholinos. We predicted that the exon 9 morpholino
would have a severe, ‘UCMD-like’ phenotype, whereas the
exon 13 morpholino would have a mild, ‘Bethlem-like’ pheno-
type. These predictions were based on the knowledge of how
the COL6A1 protein is processed and assembled into the
maturing collagen VI macromolecule and also on information
from known patient mutations (3,14,21,31,32,41). Our mor-
pholinos behaved essentially as predicted, with the exon 9
morpholino causing a very severe phenotype and the exon
Figure 8. Cyclosporin A improves motor function in col6a1 morphant zebra-
ﬁsh. Embryos were injected with morpholino at the 1–4-cell stage, treated
with either DMSO or cyclosporin A (CsA) from 21 to 24 h post fertilization,
and then examined by measuring spontaneous coiling. Values were as follows:
CTL + CsA ¼ 6.8, COL6 + DMSO ¼ 1.2, COL6 + CsA ¼ 4.1, COL6 +
p53 ¼ 1.2. (CTL ¼ control morpholino and COL6 ¼ col6a1 exon 9 morpho-
lino).
Figure 9. Cyclosporin A improves organelle ultrastructural appearance in
COL6A1 morphants. COL6A1 exon 9 morphant embryos were treated
either with DMSO or cyclosporin A (CsA). DMSO-treated embryos display
mitochondrial and endoplasmic reticular swelling. CsA treatment essentially
rescues these organellar abnormalities. M ¼ mitochondria. Scale bar ¼
500 nm.
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ﬁnal observation that supports the validity of our model is the
response to CsA. As also seen in patient biopsy samples and in
Col6a1 knockout mice (29), CsA treatment decreases apopto-
sis and improves the appearance of the mitochondria in our
zebraﬁsh morphants.
The morphant zebraﬁsh model shares many similarities to
the only previous vertebrate model of collagen VI myopathy,
the Col6a1 knockout mouse (24,25). These mice lack
expression of Col6a1 and make essentially no normal collagen
VI. They have many of the structural changes observed in
patient biopsies. In fact, it was through the study of Col6a1
knockout mice that the observations of increased apoptosis
and dysfunctional mitochondria in collagen VI myopathies
were ﬁrst made. The prominent limitation of this model,
however, is its very mild clinical phenotype. Because of
this, the Col6a1 knockout mouse is probably best considered
a model of BM. It is not clear why the mice have such a
mild phenotype, as homozygous nonsense or null mutations
in COL6A1 in humans result in a severe clinical picture con-
sistent with a diagnosis of UCMD (18,19).
The mild nature of the clinical changes in the Col6a1
knockout mice has presented a barrier for therapy develop-
ment. An example is with CsA and other proton pump modi-
ﬁers. These drugs clearly improve the structural abnormalities
in the knockout mice (25,30), but it is unclear from the mouse
studies what effect these drugs would have on more severe
disease phenotypes. One of the strengths and unique features
of our zebraﬁsh model is that the exon 9 morphant embryos
have a severe, early-onset clinical phenotype. This phenotype
is very much in line with what would be expected for an
animal model of UCMD, and thus therapeutic investigations
in our model should provide better insight into the degree of
impact that can be expected against more severe disease. We
found that CsA improves mitochondrial appearance and
decreases apoptosis in the more severely affected zebraﬁsh
morphants, similar to what has been reported for the more
mildly affected mouse model. CsA provides a partial rescue
of the severe clinical phenotype, reducing the number of paral-
yzed embryos. This demonstrated functional beneﬁt lends
support to the hypothesis that proton pump modiﬁers may
have efﬁcacy in treating humans with severe collagen IV myo-
pathies.
There are several advantages to a zebraﬁsh model of
UCMD. In addition to the clinical severity of the model, the
fact that zebraﬁsh lend themselves to facile genetic manipu-
lation enables novel insights into disease pathways and mech-
anisms. This is demonstrated by our studies of CsA. We used a
morpholino to knockdown the p53 tumor suppressor gene,
which reduced apoptosis to the levels obtained with CsA.
Unlike CsA, reducing apoptosis through p53 suppression did
not improve the motor phenotype, strongly suggesting that
CsA treatment efﬁcacy is not solely the result of reducing
mitochondrially mediated apoptosis. Whether, then, the
ability of CsA to improve motor function in our model is
related to other effects of improving mitochondrial function,
or is instead due to additional non-predicted roles of CsA, is
unclear. From our experimentation, however, it is clear that
this non-apoptosis effect of CsA on motor function is not
related to improvements in the structural appearance of the
plasma membrane and in overall myoﬁber integrity. Further
work will be necessary to pinpoint the exact interrelationship
between CsA and other proton pump modiﬁers and restoration
of muscle function in collagen VI myopathies.
Finally, our work opens up an important new avenue for
potential treatment development for UCMD, namely the
search for molecules that improve or reduce membrane
damage and myoﬁber disorganization. Small tears or leaks
in the plasma membrane are probably one of the initial
pathologic events in UCMD (16), and we demonstrate in our
zebraﬁsh model that proton pump modiﬁers such as CsA do
not improve this important aspect of the disease pathologensis.
We predict that molecules able to improve or restore
membrane integrity and/or myoﬁber organization will have a
signiﬁcant impact on disease pathogenesis. Such molecules
Figure 10. Abnormal birefringence in col6a1 morphants is not improved with
cyclosporin A treatment. (A) Birefringence in control morphants (CTL MO),
exon 9 morphants (Ex9 MO) and exon 9 morphants treated with cyclosporin A
(Ex9 MO + CsA). (B) Birefringence is signiﬁcantly reduced in exon 9 mor-
phants, an abnormality which is not improved with cyclosporin A treatment.
Human Molecular Genetics, 2010, Vol. 19, No. 12 2441theoretically should work in combination with ‘downstream’
therapeutics such as CsA. Ongoing work is focused on identi-
fying such compounds, using two other powerful aspects of
our model: the high number of affected embryos able to be
produced and the presence of an easily measurable and quan-
tiﬁable assay for myoﬁber integrity (i.e. birefringence).
Conclusion
In summary, we have used morpholino antisense technology to
create zebraﬁsh models of BM and UCMD. These models
enabled novel insights into collagen IV-related myopathy
pathogenesis, and provide a unique platform for further inves-
tigations into drug discovery in these diseases.
MATERIALS AND METHODS
Morpholinos
Morpholinos were designed to exons 9 and 13 of col6a1 and
exon 13 of col6a1 (GeneTools, Inc). A control morpholino,
with no sequence homology in the zebraﬁsh genome, was
obtained from GeneTools.
Exon 9, COL6A1: GAGAGCGGAAGACGAACCTTCATTC
Exon 13, COL6A1: AGGTAACAGTAATACTCACATCTGG
Exon 9, COL6A3: ATGATTACTACACACTTACAGGACC
p53: GCGCCATTGCTTTGCAAGAATTG
Morpholino injections
Embryos were isolated after paired matings of AB zebraﬁsh
and injected at the 1–2-cell stage using a Drummond Nano-
ject. Morpholino (4.6 nl each) was injected at a concentration
of 0.25 mM (approximate total amount of morpholino
injected ¼ 9 ng).
Assays of motor function
Spontaneous coiling was measured at 24 hpf by observing the
number of coils in a 15-s period. Touch-evoked escape
response was measured at 48 hpf using a scale from 0 to 3:
0, no movement; 1, ﬂicker of movement but no swimming;
2, movement away from probe but with impaired swimming;
3, normal swimming.
Live image analysis
Embryos were photographed at 24 and 48 hpf using a Leica
MXIII Stereoscope at ×2 with a ×4 zoom. Embryos were
anesthetized using Tricaine prior to photographing.
Histopathologic analysis
Zebraﬁsh of 48 hpf were ﬁxed overnight in Karnovsky’s ﬁxa-
tive and then processed for embedding in epon by the
Microscopy and Imaging Laboratory core facility at the Uni-
versity of Michigan. Semi-thin sections were stained with
toluidine blue and photographed using an Olympus BX-51
upright microscope. Electron microscopy was performed
using a Phillips CM-100 transmission electron microscope.
Whole-mount immunoﬂuorescence
Labeling was performed as described previously, using 48 hpf
embryos and a rabbit polyclonal antibody to collagen VI (1:50;
Abcam) (42).
TUNEL staining
TUNEL was performed on 48 hpf embryos with the ApopTag
kit using manufacturers’ instructions (Chemicon International).
CsA treatment
Morphant embryos were dechorionated at 20 hpf and then
incubated in CsA from 21 to 24 hpf. CsA was used at
100 mM and dissolved in 0.1% DMSO in egg water. Vehicle
control treatment consisted of 0.1% DMSO in egg water.
Birefringence
Birefringence was measured on 48 hpf embryos anesthetized
using tricaine. It was measured using two polarizing ﬁlters
on a Nikon AZ-100 microscope and the NIS Elements soft-
ware package (Nikon).
Statistical analysis
Statistical analysis was performed on relevant data using Stu-
dent’s two-tailed t-test and the Prism GraphPad software
package.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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